7 May 2020 - For conspiring to inflate drug prices, Apotex will pay $24 million and cooperate with the Justice Department’s investigation into the pharmaceutical industry.

The Justice Department said on Thursday that a top generic drug maker admitted to fixing prices of a popular cholesterol drug and agreed to pay $24.1 million, as part of the department’s broad crackdown on price fixing and bid rigging in the generic drug market.

Apotex settled charges with the Justice Department that it worked with other drug companies to inflate and maintain the price of the cholesterol drug, pravastatin, from 2013 to 2015.

Read New York Times article